Ocusoft has announced the journal Clinical Ophthalmology has published positive results from a clinical investigation of their flagship dry eye product, Retaine, according to a company news release. The study confirmed previous study results and demonstrated significant effects on both signs and symptoms of dry eye disease following two weeks of dosing.
“Achieving statistically significant improvements in both signs and symptoms is extremely challenging, as evidenced by the high number of clinical trials involving therapy for dry eye,” Marguerite McDonald, MD, of Ophthalmic Consultants of Long Island and Clinical Professor of Ophthalmology, NYU School of Medicine, New York, said in the news release. “The significant improvements in both signs and symptoms with Retaine indicate that it is an effective therapy for dry eye patients. The reduction in central corneal staining is especially important from a clinical perspective, as the central cornea is critical to visual function.”
Retaine ophthalmic emulsion (marketed outside the United States as Cationorm from Santen Pharmaceutical Co LTD [4536:JP]) is a cationic emulsion that contains mineral oil and targets all three layers of the tear film. In this 42 patient study following 2 weeks of dosing, there were significant reductions in corneal fluorescein staining, a hallmark sign of dry eye disease, in the superior (P=0.002), central (P=0.017), corneal sum (P=0.011) and all ocular regions combined (P=0.038). A 40% reduction was observed in mean area breakup. Significant improvements in patient evaluated symptoms including discomfort (P=0.0017), dryness (P<0.001) and grittiness (P=0.0217) provide insight into the improvement in quality of life experienced by these patients.
“We are extremely encouraged by the results of this study and the feedback we have received from both patients and physicians since launching Retaine,” Cynthia Barratt, President and CEO of Ocusoft, said in the news release. “Eye care professionals have always been and continue to be core to our business and the adoption of our products into the marketplace. Providing our physician network the ability to sell our products directly to their patients, enables a higher level of service and personalization in treating diseases like Dry Eye.”
Retaine is currently available for purchase through eye care professionals nationwide as well as at more than 6,500 Walgreens locations. Additionally, Retaine may be ordered through pharmacies and is available for direct purchase by calling (800) 233-5469 or online at www.ocusoft.com.